title: Optimizing bone health and minimizing skeletal morbidity in men with prostate cancer.
abstract: Maintaining bone health is important in the management of men with prostate cancer. Patients receiving androgen deprivation therapy are at increased risk for treatment-related osteoporosis, and patients with bone metastases are at increased risk for skeletal morbidity related to debilitating skeletal-related events (SREs). Optimizing bone health in these patients includes lifestyle modifications, calcium/vitamin D supplementation, and osteoclast-targeted agents in select high-risk patients. No agent is approved for the prevention of bone metastases. Novel systemic agents have shown a beneficial effect bone by directly affecting tumor growth. Integration of these anticancer agents with osteoclast-targeted agents warrants further investigation.
authors.affiliation: Lank Center for Genitourinary Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, 450 Brookline Avenue, Boston, MA 02215, USA.
authors.forename: Rana R
authors.initials: RR
authors.lastname: McKay
authors.forename: Mary-Ellen
authors.initials: ME
authors.lastname: Taplin
authors.forename: Toni K
authors.initials: TK
authors.lastname: Choueiri
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000517:prevention & control / Q000556:secondary* / Q000628:therapy; D001842:Bone and Bones / Q000502:physiology; D006801:Humans; D008297:Male; D058990:Molecular Targeted Therapy; D009919:Orchiectomy; D010024:Osteoporosis / Q000209:etiology*; D011471:Prostatic Neoplasms / Q000150:complications* / Q000473:pathology* / Q000628:therapy; D019275:Radiopharmaceuticals / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D050071:Bone Density Conservation Agents; D019275:Radiopharmaceuticals
keywords: Androgen deprivation therapy; Bisphosphonate; Bone metastases; Denosumab; Osteoporosis; Prostate cancer; Skeletal-related events; Zoledronic acid